These ongoing studies will determine if the results with rhIL-11 therapy found in the VWD dogs and the phase 2 dose escalation study can be translated into a safe, new treatment for VWF-deficient humans. The gene discussed is VWF; the disease is von Willebrand disease (hereditary or acquired).